At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma
- ✓ECOG performance status 0 or 1
- ✓Cohort 1: no prior systemic treatment for PDAC
- ✓Cohort 2: disease progression during administration of 5-FU- or gemcitabine-based first-line chemotherapy
- ✕Symptomatic, untreated, or actively progressing CNS metastases
- ✕History of leptomeningeal disease
- ✕Active or history of autoimmune disease or immune deficiency
- ✕History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
In Brief
A Phase 2 clinical trial evaluating Nab-Paclitaxel, Gemcitabine, and 13 other interventions for Pancreatic Adenocarcinoma. Completed, enrolled 341 participants across 23 sites in 5 countries.
Detailed Summary
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.
Study Details
Timeline
Interventions
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
Gemcitabine will be administered as per the schedule specified in the respective arm.
Oxaliplatin will be administered as per the schedule specified in the respective arm.
Leucovorin will be administered as per the schedule specified in the respective arm.
Fluorouracil will be administered as per the schedule specified in the respective arm.
Atezolizumab will be administered as per the schedule specified in the respective arm.
Cobimetinib will be administered as per the schedule specified in the respective arm.
PEGPH20 will be administered as per the schedule specified in the respective arm.
BL-8040 will be administered as per the schedule specified in the respective arm.
Selicrelumab will be administered as per the schedule specified in the respective arm.
Bevacizumab will be administered as per the schedule specified in the respective arm.
RO6874281 will be administered as per the schedule specified in the respective arm
AB928 will be administered as per the schedule specified in the respective arm.
Tiragolumab will be administered as per the schedule specified in the respective arm.
Tocilizumab will be administered as per the schedule specified in the respective arm.